Evidence map›Paper›PMID 32851789›Full record

ArticleThoracic cancer2020

Prognostic study for survival outcome following the treatment of second primary lung cancer in patients with previously resected non-small cell lung cancer.

Yijun Wu, Chang Han, Yuming Chong, Jianghao Liu, Liang Gong, Zhile Wang, Naixin Liang

Open access · goldAbstract read
In one paragraph

Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yijun Wu *Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.ORCID 0000-0002-7899-6923
Chang Han *Peking Union Medical College, Eight-year MD program, Chinese Academy of Medical Sciences, Beijing, China.
Yuming ChongPeking Union Medical College, Eight-year MD program, Chinese Academy of Medical Sciences, Beijing, China.
Jianghao LiuPeking Union Medical College, Eight-year MD program, Chinese Academy of Medical Sciences, Beijing, China.
Liang GongPeking Union Medical College, Eight-year MD program, Chinese Academy of Medical Sciences, Beijing, China.
Zhile WangDepartment of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Naixin LiangDepartment of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

Beijing Natural Science Foundation 7182132CAMS Innovation Fund for Medical Sciences (CIFMS) 2017-12M-1-009CAMS Innovation Fund for Medical Sciences (CIFMS) 2019-I2M-1-001CSCO CSCO Y-2019GENECAST-051Foundation for Key Program of Ministry of Education, China 311037Special Data Service for Oncology, The National Population and Health Scientific Data Sharing Platform NCMI-ABD02-201809Special Data Service for Oncology, The National Population and Health Scientific Data Sharing Platform NCMI-YF02N-201906
6 · The paper itself

Abstract

backgroundPatients who have previously undergone surgical resection of initial primary lung cancer (IPLC) are at high risk of developing second primary lung cancer (SPLC). There are still no standard treatments for SPLC. This study aimed to identify the prognostic factors and compare survival between the different SPLC treatment groups.

methodsSPLC patients in the Surveillance, Epidemiology, and End Results (SEER) database between 2007 and 2016 were retrospectively reviewed. Prognostic factors for SPLC were identified, using the least absolute shrinkage and selection operator (LASSO) regression and univariate Cox analysis to select variables for multivariate Cox analysis. Kaplan-Meier method plus log-rank test and restricted mean survival time (RMST) were used to compare survival outcome.

resultsA total of 665 SPLC patients were finally enrolled into the study. Multivariate Cox regression analysis revealed that male vs. female (HR = 1.82, 95% CI: 1.29-2.59, P = 0.001), tumor size of SPLC ≥1 cm vs. <1 cm (HR = 1.80, 96% CI: 1.07-3.02, P = 1.028), IPLC characteristics of squamous cell carcinoma vs. adenocarcinoma (HR = 1.89, 95% CI: 1.17-3.04, P = 0.009), clinical stage II vs. stage I (HR = 2.60, 95% CI: 1.08-6.27, P = 0.033), and T2 stage vs. T1 stage (HR = 1.68, 95% CI: 1.04-2.72, P = 0.034) indicated worse survival. SPLC patients demonstrated a five-year survival rate of 68.6% and a five-year RMST of 49.4 months. The choice of surgical procedure (wedge resection, segmentectomy and lobectomy) for both IPLC and SPLC had no significant effect on prognosis (P > 0.05). Patients that received radiotherapy for SPLC also demonstrated similar survival when compared with those that underwent surgery (P > 0.05).

conclusionsRadiotherapy and sublobar resection can be considered reasonable alternative treatments for SPLC, especially when patients are unable to tolerate lobectomy.

Indexed as

AgedCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleNeoplasms, Second PrimaryPrognosisRetrospective StudiesSurvival AnalysisLASSO regressionnon-small cell lung cancersecond primary lung cancersurvival analysis

Identifiers

PMID32851789
PMCPMC7529572
OpenAlexW3080255511

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.